Immunization with heat-killed Mycobacterium bovis bacille Calmette–Guerin (BCG) in Eurocine™ L3 adjuvant protects against tuberculosis
| Autor: | T. Jaxmar, Stefan B. Svenson, Ulf Schröder, Andrzej Pawlowski, Gunilla Källenius, Melles Haile, Beston Hamasur |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Diphtheria vaccine
Tuberculosis Chemistry Pharmaceutical Injections Subcutaneous medicine.medical_treatment Immunization Secondary Mycobacterium tuberculosis Interferon-gamma Mice Drug Delivery Systems Adjuvants Immunologic Animals Medicine Administration Intranasal Mice Inbred BALB C Mycobacterium bovis Attenuated vaccine General Veterinary General Immunology and Microbiology biology business.industry Body Weight Public Health Environmental and Occupational Health biology.organism_classification medicine.disease Survival Analysis Virology Mice Inbred C57BL Infectious Diseases Vaccines Inactivated Immunoglobulin G Immunology BCG Vaccine Molecular Medicine Emulsions Female Nasal administration business BCG vaccine Adjuvant medicine.drug |
| Zdroj: | Vaccine. 22:1498-1508 |
| ISSN: | 0264-410X |
| Popis: | The current live attenuated vaccine against tuberculosis, BCG, poses a risk of disseminated infections in immunocompromized subjects. Therefore, in this study we compared the protective effect of a heat-killed bacille Calmette–Guerin (H-kBCG) vaccine given in a new adjuvant (Eurocine™ L3) with the protection provided by the conventional live attenuated BCG vaccine in mice (C57BL/6 and BALB/c) challenged with virulent Mycobacterium tuberculosis (strain Harlingen). The H-kBCG vaccine alone, in accordance with earlier studies, did not give any or only gave slight protection compared to sham-vaccinated controls. However, the same vaccine given with Eurocine™ L3 adjuvant, either formulated as a suspension or as an emulsion, afforded significant levels of protection. This protection was at least as good as that of the control live attenuated BCG vaccine. The Eurocine™ L3 adjuvant is approved for human use as a nasal vaccine adjuvant and a successful phase I trial with nasal immunization with diphtheria vaccine has recently been performed in Sweden. Here we show that, in mice, intranasal priming with H-kBCG in Eurocine™ L3 adjuvant followed by intranasal booster resulted in the same level of protection as subcutaneous priming followed by intranasal booster. All H-kBCG formulations in the Eurocine™ L3 adjuvant elicited mycobacterial antigen-specific serum IgG and IFNγ responses. In general, among the different vaccine formulation(s) in the Eurocine™ L3 adjuvant those that produced a relatively high Th2 response, as measured by IgG1/IgG2a ratio and IFNγ production in vitro, were the most protective. In conclusion, H-kBCG in Eurocine™ L3 adjuvant could represent a safe and a more stable alternative to the conventional live BCG vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect